EP0674528A4 - Cyclodextrine et systeme de liberation de medicament a base de polymere. - Google Patents

Cyclodextrine et systeme de liberation de medicament a base de polymere.

Info

Publication number
EP0674528A4
EP0674528A4 EP94902482A EP94902482A EP0674528A4 EP 0674528 A4 EP0674528 A4 EP 0674528A4 EP 94902482 A EP94902482 A EP 94902482A EP 94902482 A EP94902482 A EP 94902482A EP 0674528 A4 EP0674528 A4 EP 0674528A4
Authority
EP
European Patent Office
Prior art keywords
cyclodextrin
delivery system
drug delivery
polymer based
based drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94902482A
Other languages
German (de)
English (en)
Other versions
EP0674528A1 (fr
Inventor
Sheng-Wan Tsao
Lyle M Bowman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Inc
Original Assignee
Insite Vision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/984,445 external-priority patent/US5332582A/en
Application filed by Insite Vision Inc filed Critical Insite Vision Inc
Publication of EP0674528A1 publication Critical patent/EP0674528A1/fr
Publication of EP0674528A4 publication Critical patent/EP0674528A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP94902482A 1992-12-02 1993-12-01 Cyclodextrine et systeme de liberation de medicament a base de polymere. Withdrawn EP0674528A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US984445 1992-12-02
US07/984,445 US5332582A (en) 1990-06-12 1992-12-02 Stabilization of aminosteroids for topical ophthalmic and other applications
US15516793A 1993-11-19 1993-11-19
US155167 1993-11-19
PCT/US1993/011651 WO1994012217A1 (fr) 1992-12-02 1993-12-01 Cyclodextrine et systeme de liberation de medicament a base de polymere

Publications (2)

Publication Number Publication Date
EP0674528A1 EP0674528A1 (fr) 1995-10-04
EP0674528A4 true EP0674528A4 (fr) 1996-06-26

Family

ID=26852057

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94902482A Withdrawn EP0674528A4 (fr) 1992-12-02 1993-12-01 Cyclodextrine et systeme de liberation de medicament a base de polymere.

Country Status (6)

Country Link
EP (1) EP0674528A4 (fr)
JP (1) JPH08503951A (fr)
CN (1) CN1103316A (fr)
AU (1) AU672862B2 (fr)
CA (1) CA2150554A1 (fr)
WO (1) WO1994012217A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW434023B (en) * 1995-09-18 2001-05-16 Novartis Ag Preserved ophthalmic composition
JP3940209B2 (ja) * 1996-11-14 2007-07-04 株式会社資生堂 可溶化化粧料
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6656456B2 (en) * 1998-11-23 2003-12-02 The Procter & Gamble Company Skin deodorizing compositions
WO2000030599A1 (fr) * 1998-11-23 2000-06-02 The Procter & Gamble Company Compositions de desodorisation et d'assainissement de la peau
JP2003529567A (ja) * 2000-03-10 2003-10-07 インサイト・ビジョン・インコーポレイテッド 後眼部眼疾患を治療および予防する方法と組成物
US6770621B2 (en) 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
JP4870314B2 (ja) 2000-05-02 2012-02-08 セラヴァンス, インコーポレーテッド シクロデキストリンを含むグリコペプチド抗生物質組成物
US6620781B2 (en) 2000-06-22 2003-09-16 Theravance, Inc. Glycopeptide carboxy-saccharide derivatives
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
WO2001098329A1 (fr) 2000-06-22 2001-12-27 Theravance, Inc. Derives polyhydroxy de glycopeptides
AU2001288120A1 (en) * 2000-09-26 2002-04-08 Kyorin Pharmaceutical Co. Ltd. Liquid prednisolone sodium phosphate preparation
CA2445606A1 (fr) * 2001-05-11 2002-11-21 Pacific Pharmaceuticals Limited Composition pharmaceutique destinee a masquer le gout de certains medicaments
EP2301549A1 (fr) * 2003-04-18 2011-03-30 Advanced Medicine Research Institute Remèdes à des affections, à usage ophtalmique
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2006040839A1 (fr) * 2004-10-15 2006-04-20 Advanced Medicine Research Institute Gouttes oculaires et trousses de traitement de maladies oculaires
JP2007177149A (ja) * 2005-12-28 2007-07-12 Shield Lab:Kk チオクト酸又はジヒドロリポ酸と分岐鎖シクロデキストリンとの包接化合物
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
HRP20121045T1 (hr) * 2007-12-21 2013-01-31 Aop Orphan Pharmaceuticals Ag Farmaceutska smjesa za parenteralnu primjenu antagonista beta-adrenoreceptora ultrakratkog djelovanja
US10201548B2 (en) * 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
US10980818B2 (en) 2009-03-06 2021-04-20 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
US20120271272A1 (en) 2010-10-15 2012-10-25 Iscience Interventional Corporation Device for ocular access
EP2916827B1 (fr) 2012-11-08 2020-06-10 Clearside Biomedical Inc. Procédés pour le traitement de maladies oculaires chez des sujets humains
WO2014127015A1 (fr) * 2013-02-12 2014-08-21 Ys Pharm Tech Préparations d'épinéphrine pour des produits médicinaux
SG10201702674PA (en) 2013-05-03 2017-06-29 Clearside Biomedical Inc Apparatus and methods for ocular injection
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
CN103990137A (zh) * 2014-04-30 2014-08-20 福建融和药业有限公司 一种粘膜粘附性聚合物眼用药物的缓释剂
WO2017139375A1 (fr) 2016-02-10 2017-08-17 Clearside Biomedical, Inc. Kit d'injection oculaire, conditionnement et procédés d'utilisation
CA3062845A1 (fr) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systemes et methodes pour l'administration de medicaments par voie ophtalmique
EP3496680B1 (fr) 2016-08-12 2024-10-02 Clearside Biomedical, Inc. Dispositif de réglage de la profondeur d'insertion d'une aiguille pour administration de médicament
WO2018204515A1 (fr) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Procédés d'administration ciblée de médicament au moyen d'une microaiguille
CN109136177B (zh) * 2018-08-03 2021-09-17 湖南大学 一种地塞米松缓释体系以及一种成骨分化诱导液和应用
RU2740287C1 (ru) * 2019-08-30 2021-01-12 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) 3д-матриксная структура для доставки лекарственных препаратов
CN115380899A (zh) * 2022-08-30 2022-11-25 陕西科技大学 一种凝胶型腐植酸缓释农药及其制备方法
WO2024097388A1 (fr) * 2022-11-03 2024-05-10 Arizona Board Of Regents On Behalf Of The University Of Arizona Systèmes et méthodes de surveillance du métabolisme des acides gras

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300526A2 (fr) * 1987-07-01 1989-01-25 Janssen Pharmaceutica N.V. Compositions pharmaceutiques antivirales contenant des cyclodextrines
EP0399716A1 (fr) * 1989-05-24 1990-11-28 Innovet, Inc. Composition hypoallergénique stéroide à activité anesthésiante/hypnotique
EP0463653A1 (fr) * 1990-06-07 1992-01-02 PHARMACIA S.p.A. Formulations galéniques contenant des cyclodextrines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
IE63392B1 (en) * 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300526A2 (fr) * 1987-07-01 1989-01-25 Janssen Pharmaceutica N.V. Compositions pharmaceutiques antivirales contenant des cyclodextrines
EP0399716A1 (fr) * 1989-05-24 1990-11-28 Innovet, Inc. Composition hypoallergénique stéroide à activité anesthésiante/hypnotique
EP0463653A1 (fr) * 1990-06-07 1992-01-02 PHARMACIA S.p.A. Formulations galéniques contenant des cyclodextrines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9412217A1 *

Also Published As

Publication number Publication date
EP0674528A1 (fr) 1995-10-04
AU5684194A (en) 1994-06-22
CN1103316A (zh) 1995-06-07
AU672862B2 (en) 1996-10-17
CA2150554A1 (fr) 1994-06-09
WO1994012217A1 (fr) 1994-06-09
JPH08503951A (ja) 1996-04-30

Similar Documents

Publication Publication Date Title
EP0674528A4 (fr) Cyclodextrine et systeme de liberation de medicament a base de polymere.
US5525634B1 (en) Colonic drug delivery system
EP0662851A4 (fr) Systeme d'administration de medicaments.
AU664807B2 (en) Drug delivery system
AU3127697A (en) Intravenous catheter and delivery system
AU8935591A (en) Drug delivery system and method
IL117706A (en) Powdered drug storage and delivery system
AU4989993A (en) Drug delivery system
ZA988203B (en) Aerosol medication delivery apparatus and system.
AU3204995A (en) Closed drug delivery system
EP0643976A3 (fr) Dispositif d'administration cardioplégique.
AU9617698A (en) Polymeric systems for drug delivery and uses thereof
ZA967502B (en) Medicament delivery device.
AU7676894A (en) Convection-enhanced drug delivery
AU3290397A (en) Gastric-retentive oral controlled drug delivery system with enhanced retention properties
ZA965931B (en) Transcorneal drug delivery system.
AU4406793A (en) Water-soluble polymeric carriers for drug delivery
EP0671165A3 (fr) Système injectable pour la délivrance d'un médicament à base de collagène et son utilisation.
AU1719800A (en) Drug delivery systems and methods
AU4468197A (en) Hyaluronic drug delivery system
AU660290B2 (en) Multiple drug delivery system
GB9325330D0 (en) Fluorocyclodextrin drug delivery system
EP0636363A3 (fr) Système pour la délivrance d'un médicament.
AU1671997A (en) Drug delivery system using galactoxyloglucan
GB2292887B (en) Drug delivery system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950529

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19960509

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980202

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980813